本文關鍵詞： 肝母細胞瘤 治療 預后 兒童　出處：《臨床兒科雜志》2017年02期 　論文類型：期刊論文

【摘要】：目的探討肝母細胞瘤(HB)患兒的預后。方法回顧性收集2010年9月至2015年2月初治HB患兒的病歷及隨訪資料,總結臨床療效和預后。結果共納入HB患兒36例,男23例、女13例,中位年齡20個月。36例患兒的中位隨訪時間37個月(7~71個月)。36例患兒死亡8例,參照美國兒童腫瘤研究組(POG/CCG)亞組分析,Ⅰ、Ⅱ期患兒預后明顯好于Ⅲ、Ⅳ期,胎兒型患兒預后明顯優(yōu)于其他亞型(P0.05)。35例患兒疾病初期甲胎蛋白(AFP)水平增高,存活者治療后AFP水平均降至正常;8例死亡患兒中3例復發(fā)后AFP水平增高,5例經輔助化療AFP水平持續(xù)不降。初診時乳酸脫氫酶(LDH)升高組(245 U/L)及C反應蛋白(CRP)升高組(5 mg/L)存活率明顯低于正常組,天冬氨酸氨基轉移酶(AST)≥80 U/L的患兒存活率明顯低于AST80 U/L的患兒,差異均有統(tǒng)計學意義(P0.05)。結論血清AFP可作為HB復發(fā)和預后的監(jiān)測指標。POG/CCG分期、病理分型是評估HB預后的重要因子,血清LDH、CRP、AST水平升高可能與HB患兒預后不良有關。
[Abstract]:Objective to investigate the prognosis of children with Hepatoblastoma (HBB). Methods the medical records and follow-up data of children with HB from September 2010 to early February 2015 were collected retrospectively. Results 36 children with HB were included, including 23 males and 13 females. The median follow-up time was 37 months, 7 ~ 71 months, and 36 cases died. According to the analysis of POG / CCG subgroup of American Children's Cancer Research Group, the median age was 20 months. The prognosis of stage 鈪，

本文編號：1477828